Welcome to the e-CCO Library!

DOP01: Extracellular Nicotinamide Phosphoribosyltransferase (eNAMPT): possible new target and biomarker in inflammatory bowel diseases
Year: 2019
Source:

ECCO '19 Copenhagen

Authors:

G. Colombo*1, C. Travelli1, C. Porta1, G. Stocco2, F. Malavasi3, A. A. Genazzani1

Created: Friday, 22 February 2019, 9:41 AM
DOP01: The effect of vedolizumab on CD8 T cell repertoire homogeneity and blood-gut trafficking in patients with inflammatory bowel disease
Year: 2023
Source: ECCO’23 Copenhagen
Authors: Williams, K.(1);Shows, D.(2);Kongala, R.(2);Clarke, A.(3);Lord, J.(2)*;
Created: Friday, 14 July 2023, 10:43 AM
DOP02 The dose-dependent effect of enteral nutrition on faecal microbial metabolites of healthy volunteers
Year: 2020
Source:

ECCO'20 Vienna

Authors:

V. Svolos1, K. Gkikas1, V. Rizou1, E. Christina1, P. Kapranos1, J. Kleingunnewiek1, J.P. Seenan2, J. Macdonald2, D.R. Gaya3, R. Hansen4, R.K. Russell4, K. Gerasimidis1

Created: Thursday, 30 January 2020, 10:12 AM
DOP020: Higher vedolizumab levels are associated with deep remission in patients with Crohn's disease and ulcerative colitis on maintenance therapy with vedolizumab
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Yarur A.*1, Bruss A.1, Jain A.2, Kondragunta2 V.2, Hester K.2, Luna T.2, Agrawal D.1, Patel A.1, Fox C.1, Werner S.1, Naik S.2, Stein D.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP020: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohns disease: pooled results from the ASTIC trial
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

J. Lindsay*1, M. Allez2, M. Clark3, M. Labopin4, E. Ricart5, G. Rogler6, M. Rovira7, J. Satsangi8, D. Farge9, C. Hawkey3

Created: Friday, 22 February 2019, 9:49 AM
DOP020: Thiopurine monotherapy still has a place in the treatment of patients with mild-to-moderate Crohn’s disease in the biological era
Year: 2018
Source: ECCO '18 Vienna
Authors:

B. Verstockt1,2*, L. Boets1, G. Van Assche1,2, S. Vermeire1,2, M. Ferrante1,2

Created: Thursday, 21 February 2019, 9:14 AM
DOP021: Immunosuppressive and anti-TNF treatment is associated with a lower risk of migration from B1-to-B3-stage in Crohn’s disease: 10-year follow-up data from the Swiss IBD cohort study
Year: 2018
Source: ECCO '18 Vienna
Authors:

P. Cernoch1, N. Fournier2, M. Scharl1, J. Zeitz3, B. Morell1, T. Greuter1, P. Schreiner1, B. Misselwitz1, E. Safroneeva4, A. Schoepfer5, S.R. Vavricka6, G. Rogler1, L. Biedermann on behalf of the Swiss IBD Cohort Study Group7*

Created: Thursday, 21 February 2019, 9:14 AM
DOP021: Long-term effectiveness and safety of vedolizumab in patients with Crohn's disease: 5-year cumulative exposure of GEMINI 2 completers rolling into the GEMINI open-label extension study
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Vermeire S.*1, Loftus E.V.2, Colombel J.-F.3, Feagan B.4, Sandborn W.5, Sands B.6, Danese S.7, D'Haens G.8, Kaser A.9, Panaccione R.10, Rubin D.11, Shafran I.12, O'Byrne S.13, Geransar P.13, Previtali A.14, Khalid J.M.15, Kaviya A.16

Created: Wednesday, 20 February 2019, 10:36 AM
DOP021: Long-term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohns disease: 10 years of Milan experience without CD34+ cell selection
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

A. Cassinotti*1, F. Onida2, C. Annaloro2, G. Saporiti2, M. Fichera1, M. Daperno3, B. Motta2, P. Fociani4, E. Tagliaferri2, G. Sampietro5, D. Vincenti2, A. Gregorini2, G. Maconi1, M. Nebuloni6, A. Cortelezzi2, S. Ardizzone1

Created: Friday, 22 February 2019, 9:49 AM
DOP022: Tacrolimus suppositories as induction therapy for refractory ulcerative proctitis: a randomised controlled trial
Year: 2018
Source: ECCO '18 Vienna
Authors:

J.E. Kreijne1*, M.R. Lie1, G. Dijkstra2, M. Löwenberg3, G. van Assche4, R.L. West5, D. van Noord5, A.A. van der Meulen - de Jong6, B.E. Hansen1,7, A.C. de Vries1, C.J. van der Woude1

Created: Thursday, 21 February 2019, 9:14 AM
DOP022: Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for inflammatory bowel disease
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

L. Carter1, R. Morgan1, C. Lesch1, M. Spahr1, L. Franchi2, I. Monteleone3, G. Monteleone3, G. Glick2, H. J. Wilkins1, P. Higgins*2

Created: Friday, 22 February 2019, 9:49 AM
DOP022: Vedolizumab and anti-TNFα treatment effectiveness in patients with IBD treated in Germany: a retrospective chart review
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ehehalt R.*1, Schubert S.2, Stein D.3, Lambrelli D.4, Bassel M.5, Orzechowski H.-D.6, Minda K.7, Khalid J.M.8

Created: Wednesday, 20 February 2019, 10:36 AM
DOP023: Predictors of clinical and endoscopic response with vedolizumab for the treatment of moderately-severely active ulcerative colitis: results from the US VICTORY consortium
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Dulai P.*1, Meserve J.1, Hartke J.2, Chilukuri P.2, Chaudrey K.3, Koliani-Pace J.L.4, Kochhar G.5, Parikh M.P.5, Shmidt E.6, Hirten R.6, Luo M.7, Barocas M.7, Lasch K.7, Sultan K.8, Swaminath A.9, Bohm M.10, Lukin D.11, Hudesman D.12, Shen B.5, Siegel C.A.4, Sands B.E.6, Colombel J.-F.6, Kane S.3, Loftus Jr. E.V.3, Singh S.1, Sandborn W.J.1, Boland B.S.1

Created: Wednesday, 20 February 2019, 10:36 AM
DOP023: Safety and efficacy of a novel IV targeted pegylated liposomal prednisolone product (Nanocort): results from a phase 2a study in patients with active ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

G. van Assche1, P. Rutgeerts1, M. Ferrante1, M. Noman1, H. Fidder2, B. Oldenburg2, J. Metselaar3, 4, S. Vermeire*1

Created: Friday, 22 February 2019, 9:49 AM
DOP023: Tofacitinib for the treatment of ulcerative colitis: up to 4.4 years of safety data from global clinical trials
Year: 2018
Source: ECCO '18 Vienna
Authors:

W.J. Sandborn1, J. Panés2*, G.R. D’Haens3, B.E. Sands4, C. Su5, M. Moscariello5, T.V. Jones5, R.D. Pedersen5, G.S. Friedman5, N. Lawendy5, G. Chan5

Created: Thursday, 21 February 2019, 9:14 AM
DOP024: Electrical vagus nerve stimulation as an innovative treatment in inflammatory bowel diseases
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

V. Sinniger1, 2, 3, S. Pellissier3, 4, D. Hoffmann5, C. Trocmé6, L. Vercueil3, 7, 
D. Clarençon3, 8, B. Bonaz*3, 9

Created: Friday, 22 February 2019, 9:49 AM
DOP024: Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
Year: 2018
Source: ECCO '18 Vienna
Authors:

S. Hanauer1, R. Panaccione2, S. Danese3, A. Cheifetz4, W. Reinisch5*, P.D.R. Higgins6, D.A. Woodworth7, H. Zhang7, G.S. Friedman7, N. Lawendy7, D. Quirk7, C.I. Nduaka7, C. Su7

Created: Thursday, 21 February 2019, 9:14 AM
DOP024: Vedolizumab clinical and post-marketing safety experience of opportunistic infections
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Ng S.C.*1, Palo W.2, Blake A.3, Rana-Khan Q.4, Bhayat F.5

Created: Wednesday, 20 February 2019, 10:36 AM
DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in ulcerative colitis
Year: 2016
Source: ECCO '16 Amsterdam
Authors:

W. Sandborn1, 2, B. Bhandari3, R. Fogel4, J. Onken5, E. Yen6, E. Huntzicker6, Y. Xin6, D. French6, J. Silverman6, B. Kanwar6, M. Subramanian6, J. McHutchison6, S. Lee7, L. Shackelton8, L. Stitt8, R. Pai9, B. Levesque*2, G. D’Haens10, 11, B. Feagan8, 12

Created: Friday, 22 February 2019, 9:49 AM
DOP025: Efficacy of vedolizumab on extraintestinal manifestation in patients with inflammatory bowel disease: a post-hoc analysis of the OBSERV-IBD cohort from the GETAID
Year: 2017
Source: ECCO '17 Barcelona
Authors:

Tadbiri S.*1, Grimaud J.C.2, Peyrin-Biroulet L.3, Filippi J.4, Pariente B.5, Roblin X.6, Buisson A.7, Stefanescu C.8, Trang-Poisson C.9, Altwegg R.10, Marteau P.11, Vaysse T.12, Bourrier A.13, Nancey S.14, Laharie D.15, Allez M.16, Bouhnik Y.8, Amiot A.17

Created: Wednesday, 20 February 2019, 10:36 AM